Clinical Trial Participation

Consider making a personal contribution to research by participating in a clinical trial. Clinical research may lead to the discovery of new possibilities in the control or the delay of Parkinsonian symptoms. All study-related care is provided at no charge, including:

  • Physician visits and physical examinations
  • Laboratory services
  • Study medication

For information about participation in clinical trials, please contact the Movement Disorders Research Office by phone at 312-503-0755, by fax 312-503-0787 or by email: PDclinicaltrials@northwestern.edu.

Current Recruiting Clinical Trials

Download Current Recruiting Clinical Trials (PDF)

Early Parkinson's Disease

PPMI:

The objective of this study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies. Study is recruiting for PD subjects not requiring therapy for at least 6 months and non PD subjects.

Funded by the Michael J. Fox Foundation

Participate in a research update call on Tuesday, December 13th

FS-ZONE:

The primary objective of the study is to assess the impact of prioglitazone on the progression of PD in order to assess whether it is ineffective to proceed with further study of this agent.

Funded by the National Institute of Neurological Disorders & Stroke

Advanced Disease

Open-Label Duodopa:

This is the continuation of the Double-Blind Duodopa study. Participants who wish to continue using the intestinal gel will roll over into this study. The goal is to continuously deliver carbidopa-levodopa medication in gel form directly into the small intestine using a tube/pump system. Participation lasts 12 months, with the option to continue with treatment after the study is over.

Funded by Abbott Products, Inc.

SETTLE:

The objectives of this trial are to evaluate the safety and efficacy of two doses of safinamide (50 and 100 mg p.o. q.a.m.), compared to placebo, as add-on therapy in subjects with idiopathic Parkinson’s Disease with motor fluctuations who are currently receiving a stable dose of levodopa and who may be also receiving a stable dose of a dopamine agonist, anticholinergic and/or amantadine.

Funded by EMD Serono

AMANTADINE:

This study is looking at the potential benfits of the FDA approved medication amanatadine on freezing of gait. Patients will be required to be ON and OFF medication. Participation is 4 clinic visits and 1 telephone call.

This is an investigator initiated study – funded by the Principal Investigator

Sleep Disorders in Parkinson's Disease

Light Study:

The purpose of this study is to evaluate the effectiveness of light treatment on excessive daytime sleepiness in patients with Parkinson’s disease. This study requires 2 one night stays in the hospital, 3 clinic visits, and 2 weeks of light box treatment done in the subject’s home.

Funded by the National Parkinson Foundation

Circadian Rhythms in PD:

This study is being done in order to look at how the biological clock works in patients with Parkinson’s disease by examining sleep patterns, daytime sleepiness, and melatonin and cortisol blood levels. Participation lasts 2 weeks, which includes 2 sleep studies and one 24-hour period of blood draws. Participants are compensated for their time and travel.

Funded by the National Parkinson Foundation and the American Academy of Neurology Foundation

For information about participation in clinical trials, please contact the Movement Disorders Research Office by phone at 312-503-0755, by fax 312-503-0787 or by email: PDclinicaltrials@northwestern.edu